Nakanjako interned at
Mulago Hospital in Internal Medicine and Obstetrics and Genecology, from 1998 until 1999. She spent another year at the same hospital as a medical officer. She then spent two years as a specialist medical officer at the
CDC field station in
Tororo, Uganda. In 2002, she returned to Mulago to pursue her master's degree.[3]
After her MMed studies she focused on clinical research in
HIV/
AIDS and she started lecturing in internal medicine at Makerere in 2007. Following her PhD studies, the
Welcome Trust awarded her a scholarship to undertake a postdoctoral fellowship at Makerere, based at the Infectious Diseases Institute of the university.[3]
Makerere University appointed Nakanjako as Associate Professor of Medicine in 2013, serving in that capacity for five years. In 2018, she made full Professor.[3]
Other considerations
Professor Nakanjako has authored or co-written over 100 peer-reviewed articles, in the areas of her medical expertise in different medical journals.[4] Some of them include; Effects of HIV infection and ART on phenotype and function of circulating monocytes, natural killer, and innate lymphoid cells.[5] Access to HIV/AIDS care for mothers and children in sub-Saharan Africa: adherence to the postnatal PMTCT program.[6] Diversity of vaginal microbiota in sub-Saharan Africa and its effects on HIV transmission and prevention.[7] Subclinical Atherosclerosis among HIV-Infected Adults Attending HIV/AIDS Care at Two Large Ambulatory HIV Clinics in Uganda.[8] Low HIV viral suppression rates following the intensive adherence counseling (IAC) program for children and adolescents with viral failure in public health facilities in Uganda.[9] Acceptance of routine testing for HIV among adult patients at the medical emergency unit at a National Referral Hospital in Kampala, Uganda.[10] High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort.[11] Use of RDTs to improve malaria diagnosis and fever case management at primary health care facilities in Uganda.[12] Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda.[13] Mentorship needs at academic institutions in resource-limited settings: a survey at makerere university college of health sciences.[14] Atorvastatin reduces T-cell activation and exhaustion among HIV-infected cART-treated suboptimal immune responders in Uganda: a randomised crossover placebo-controlled trial.[15] Challenges faced by caregivers of virally non-suppressed children on the intensive adherence counselling program in Uganda: a qualitative study.[16] Predictors and outcomes of mycobacteremia among HIV-infected smear- negative presumptive tuberculosis patients in Uganda.[17] Acceptability and predictors of uptake of Anti-retroviral Pre-exposure Prophylaxis (PrEP) among fishing communities in Uganda: A cross-sectional discrete choice experiment survey.[18] Frequency and impact of suboptimal immune recovery on first-line antiretroviral therapy within the International Epidemiologic Databases to evaluate AIDS in East Africa.[19] and Strategies for retention of heterosexual men in HIV care in sub-Saharan Africa: A systematic review.[20]